Abstract: A data system may adjust the input data to a machine learning model based on a change in a consent associated with a patient. The data system may detect the change in the consent associated with the patient. The data system may identify private data associated with the change in the consent. The data system may identify a machine learning model to which the private data has contributed. The data system may determine input data that has contributed to the machine learning model. The input data may include the private data. The data system may determine, based on the change in the consent associated with the private data, whether to replace the private data in the input data with replacement data. The data system may adjust the input data based on the determination of whether to replace the private data in the input data with replacement data.

Abstract: Patient health data and consent data may be managed. Conditional consent by a patient may be provided for utilizing their private health data in one or more of the following: the adaptation of procedures, instrument operation, system configuration, display of results and/or plans for device usage. The patient granted consent may be associated with one or more condition(s), stipulation(s), and/or limitations of the scope, duration, and/or usage of their health data. A health data management system may check that patient data is only being used in accordance with the consent data (e.g., for the agreed upon purpose(s) and for the agreed upon time).

Abstract: The present application provides PEI compounds comprising a linker, PEI-polypeptide conjugates (e.g., PEI-antibody conjugates), and complexes thereof comprising a biologically active molecule. Methods of preparing and using the compounds, conjugates and complexes are further provided. The PEI-polypeptide conjugates and complexes are useful for delivering biologically active molecules to the cytoplasm of cells and promoting release of the biologically active molecules from the endo-lysosomal pathway.

Abstract: The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates, toxin-(biocompatible polymer) conjugates, antibody-(biocompatible polymer) conjugates, and bispecific antibodies) comprising acyl donor glutamine-containing tags and amine donor agents. In one aspect, the invention provides an engineered Fc-containing polypeptide conjugate comprising the formula (Fc-containing polypeptide)-T-A, wherein T is an acyl donor glutamine-containing tag engineered at a specific site or comprises an endogenous glutamine made reactive by the Fc-containing polypeptide engineering, wherein A is an amine donor agent, and wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag or the endogenous glutamine. The invention also provides methods of making engineered polypeptide conjugates using transglutaminase.

Abstract: The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates, toxin-(biocompatible polymer) conjugates, antibody-(biocompatible polymer) conjugates, and bispecific antibodies) comprising acyl donor glutamine-containing tags and amine donor agents. In one aspect, the invention provides an engineered Fc-containing polypeptide conjugate comprising the formula (Fc-containing polypeptide)-T-A, wherein T is an acyl donor glutamine-containing tag engineered at a specific site or comprises an endogenous glutamine made reactive by the Fc-containing polypeptide engineering, wherein A is an amine donor agent, and wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag or the endogenous glutamine. The invention also provides methods of making engineered polypeptide conjugates using transglutaminase.

Abstract: The present application provides PEI compounds comprising a linker, PEI-polypeptide conjugates (e.g., PEI-antibody conjugates), and complexes thereof comprising a biologically active molecule. Methods of preparing and using the compounds, conjugates and complexes are further provided. The PEI-polypeptide conjugates and complexes are useful for delivering biologically active molecules to the cytoplasm of cells and promoting release of the biologically active molecules from the endo-lysosomal pathway.

Abstract: The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates, toxin-(biocompatible polymer) conjugates, antibody-(biocompatible polymer) conjugates, and bispecific antibodies) comprising acyl donor glutamine-containing tags and amine donor agents. In one aspect, the invention provides an engineered Fc-containing polypeptide conjugate comprising the formula (Fc-containing polypeptide)-T-A, wherein T is an acyl donor glutamine-containing tag engineered at a specific site or comprises an endogenous glutamine made reactive by the Fc-containing polypeptide engineering, wherein A is an amine donor agent, and wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag or the endogenous glutamine. The invention also provides methods of making engineered polypeptide conjugates using transglutaminase.

Abstract: The present invention relates to methods for the treatment of reducing LDL-cholesterol levels in a subject infected with hepatitis C virus (HCV) or at high risk of contracting HCV comprising administration to the subject in need thereof a therapeutically effective amount of an antagonist antibody which specifically binds to a human PCSK9 protein. The subject treatment can be used in the prevention and/or treatment of cholesterol and lipoprotein metabolism disorders, including hypercholesterolemia, dyslipidemia, hyperlipidemia, atherosclerosis, acute coronary syndrome and, more generally, cardiovascular disease (CVD).

Abstract: The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates, toxin-(biocompatible polymer) conjugates, antibody-(biocompatible polymer) conjugates, and bispecific antibodies) comprising acyl donor glutamine-containing tags and amine donor agents. In one aspect, the invention provides an engineered Fc-containing polypeptide conjugate comprising the formula (Fc-containing polypeptide)-T-A, wherein T is an acyl donor glutamine-containing tag engineered at a specific site or comprises an endogenous glutamine made reactive by the Fc-containing polypeptide engineering, wherein A is an amine donor agent, and wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag or the endogenous glutamine. The invention also provides methods of making engineered polypeptide conjugates using transglutaminase.

Abstract: The present technology relates to biocidal compositions and methods that contain and utilize at least one biocidal agent and at least one potentiator system wherein the resultant combination has an enhanced biocidal efficacy. The present technology also discloses a rapid screening assay for determining biocidal compositions with enhanced efficacy, e.g., a microbial contact kill time of 5 minutes or less. Further, the present technology provides a method of determining biocidally effective concentrations of biocidal compositions comprising at least one biocidal agent and at least one potentiator system.

Abstract: A tunable optical diffraction grating apparatus, such as but not limited to a tunable Fresnel zone lens apparatus, includes a plurality of symmetric repeating structures (i.e., typically concentric rings) located over a substrate and comprising a material susceptible to a transparent to opaque transition for a designated radiation wavelength. The tunable optical diffraction grating apparatus also includes a means for separately effecting the transparent to opaque transition for each of the plurality of symmetric repeating structures to provide a plurality of transparent zones each comprising a variable first sub-plurality of adjacent transparent symmetric repeating structures alternating and interposed between a plurality of opaque zones each comprising a variable second sub-plurality of adjacent opaque symmetric repeating structures. Also included are a method for fabricating the tunable optical diffraction grating apparatus and a method for operating the tunable optical diffraction grating apparatus.

Abstract: Infrared metamaterial arrays containing Au elements immersed in a medium of benzocyclobutene (BCB) were fabricated and selectively etched to produce small square flakes with edge dimensions of approximately 20 ?m. Two unit-cell designs were fabricated: one employed crossed-dipole elements while the other utilized square-loop elements.

Abstract: A magnetic angle sensor system for determining a shaft angle for one or more pivoting or rotating shaft means. The or each of said shaft means is provided with means adapted to generate a magnetic field, such that means can be energised in turn to induce a magnetic field in a detector. In a first step the sensor arrangement measures the background field in the absence of any current in the wire or solenoid, such that the angle of the shaft means can be determined from the magnetic field in the solenoid and the background field. The invention concerns the use of an evoked response field whether alternating or steady whereby the angle is determined by the difference in field when the evoking magnetic stimulus is present from when it is absent.

Abstract: The present technology relates to biocidal compositions and methods that contain and utilize at least one biocidal agent and at least one potentiator system wherein the resultant combination has an enhanced biocidal efficacy. The present technology also discloses a rapid screening assay for determining biocidal compositions with enhanced efficacy, e.g., a microbial contact kill time of 5 minutes or less. Further, the present technology provides a method of determining biocidally effective concentrations of biocidal compositions comprising at least one biocidal agent and at least one potentiator system.

Abstract: The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates, toxin-(biocompatible polymer) conjugates, antibody-(biocompatible polymer) conjugates, and bispecific antibodies) comprising acyl donor glutamine-containing tags and amine donor agents. In one aspect, the invention provides an engineered Fc-containing polypeptide conjugate comprising the formula (Fc-containing polypeptide)-T-A, wherein T is an acyl donor glutamine-containing tag engineered at a specific site or comprises an endogenous glutamine made reactive by the Fc-containing polypeptide engineering, wherein A is an amine donor agent, and wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag or the endogenous glutamine. The invention also provides methods of making engineered polypeptide conjugates using transglutaminase.

Abstract: Infrared metamaterial arrays containing Au elements immersed in a medium of benzocyclobutene (BCB) were fabricated and selectively etched to produce small square flakes with edge dimensions of approximately 20 ?m. Two unit-cell designs were fabricated: one employed crossed-dipole elements while the other utilized square-loop elements.

Abstract: A tunable optical diffraction grating apparatus, such as but not limited to a tunable Fresnel zone lens apparatus, includes a plurality of symmetric repeating structures (i.e., typically concentric rings) located over a substrate and comprising a material susceptible to a transparent to opaque transition for a designated radiation wavelength. The tunable optical diffraction grating apparatus also includes a means for separately effecting the transparent to opaque transition for each of the plurality of symmetric repeating structures to provide a plurality of transparent zones each comprising a variable first sub-plurality of adjacent transparent symmetric repeating structures alternating and interposed between a plurality of opaque zones each comprising a variable second sub-plurality of adjacent opaque symmetric repeating structures. Also included are a method for fabricating the tunable optical diffraction grating apparatus and a method for operating the tunable optical diffraction grating apparatus.

Abstract: A magnetic angle sensor system for determining a shaft angle for one or more pivoting or rotating shaft means. The or each of said shaft means is provided with means adapted to generate a magnetic field, such that means can be energised in turn to induce a magnetic field in a detector. In a first step the sensor arrangement measures the background field in the absence of any current in the wire or solenoid, such that the angle of the shaft means can be determined from the magnetic field in the solenoid and the background field. The invention concerns the use of an evoked response field whether alternating or steady whereby the angle is determined by the difference in field when the evoking magnetic stimulus is present from when it is absent.

Abstract: An array of two or more tunable electro-optical reflecting elements where the phase response of one or more elements may be adjusted by a variety of approaches including, but not limited to: a liquid crystal superstrate, schottky contact(s), ultra-violet radiation pulses, and illumination of photoconductive substrates. Methods and apparatus for direct and/or adaptive control of phase response via the above approaches are also discussed.

Abstract: The present technology relates to biocidal compositions and methods that contain and utilize at least one biocidal agent and at least one potentiator system wherein the resultant combination has an enhanced biocidal efficacy. The present technology also discloses a rapid screening assay for determining biocidal compositions with enhanced efficacy, e.g., a microbial contact kill time of 5 minutes or less. Further, the present technology provides a method of determining biocidally effective concentrations of biocidal compositions comprising at least one biocidal agent and at least one potentiator system.